Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Flucitasone and salmeterol (Seretide®) |
For existing patients, for paediatric use only (i.e. up to 18 years of age) - APC listing of current formulary brands |
|
|
|
Flucitasone furoate (Avamys) |
Approved for use in children and adults. Previous APC decision reviewed in December 2015. |
|
|
Flucitasone inhaler (Flixotide) evohaler 125 / Fluticasone accuhaler 250 |
For paediatric use only |
|
|
|
Flucitasone inhaler (Flixotide) evohaler 50 / Fluticasone accuhaler 50, 100 |
For paediatric use only |
|
|
|
Flucitasone propionate and azelastine (Dymista®) |
Third line option for adults and children over 12 with moderate to severe allergic rhinitis who have failed ot respond to a steroid nasal spray with the addition of an oral antihistamine. Follow APC treatment algorithm. |
|
|
Flunarazine tablets |
Not licensed in the UK. Licensed in Europe and Ireland - preventative management in primary headache. |
|
|
|
Fluocinolone acetonide 0.025% (Synalar 1 in 10 dilution®) |
Mild - for use in paediatrics |
|
|
|
Fluorometholone 0.1% eye drops (5ml) |
Specialist ophthalmologist recommendation |
|
|
|
Fluorouracil injection |
|
For hospital use only |
|
|
Flupentixol decanoate injection |
Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion). |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- Next page
- Last page
